InfuSystem publishes investor presentation on home healthcare platform for complex therapies outside hospitals
INFU•FY 2025 financial highlights and growth priorities
For FY 2025, net revenue was $143.4 million; adjusted EBITDA was $31.5 million; adjusted EBITDA margin was 21.9%; and operating cash flow was $24.4 million.
Liquidity of $58.2 million was positioned to fund growth initiatives, including selective tuck-in acquisitions.
Patient Services accounted for about 60% of revenue at $86 million-plus, while Device Solutions accounted for about 40% at $56 million-plus.
The company is targeting a sustained adjusted EBITDA margin of 22% to 25%, supported by ERP cost roll-off and a shift toward less capital-intensive growth.
Investor presentation outlines home healthcare platform
InfuSystem outlined a home healthcare platform for complex therapies outside hospitals, combining reimbursement support, logistics, and 24/7 clinical services.
